Ascelia Pharma AB (publ) (ACE) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Acellia Pharma Q3 2025 report presentation. For the first part of the conference, participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Magnus Corfitzen, CSO Andreas Norlin, and Deputy CEO Julie Warris Brogren. Please go ahead. Hi, everyone, and welcome to the webcast for Celia Fama Q3 Financial Report 2025. On this call, we will be making forward-looking statements. On today's call, we will start with recent key events and then head into our portfolio update before moving to financials and priorities ahead. After the presentation, we will open up for questions as usual. At Acelia Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We're based in Malmö, Sweden, and are listed on nasdaq.com. We have two drugs in our pipeline. Orbic Lans is in the registration phase as we have successfully completed the pivotal phase three clinical study, SPICLE, and have submitted the new drug application to the FDA. The FDA is currently reviewing the application. OrbeGlance has orphan drug designation from the FDA and is targeting an addressable market opportunity of $800 million. Our other asset, Oncral, is a patented tablet formulation of virenotekin with encouraging results in phase one and potential to treat a range of solid tumors. We have a clinical collaboration with Tidal Oncology and are initially targeting treatment of gastric cancer. The key milestone in the third quarter was our submission of the Overglans NDA to the FDA, which took place in early September. Also in September, Fenja Capital converted their 7.5 million Swedish krono...